Expert Viewpoints in MF

CME

Expert Viewpoints in Myelofibrosis: Advancing Treatment Strategies With Next-Generation Therapeutics

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: February 07, 2024

Expiration: February 06, 2025

Abdulraheem Yacoub
Abdulraheem Yacoub, MD

Activity

Progress
1 2
Course Completed

Introduction

In this activity, Abdulraheem Yacoub, MD, reviews key evidence informing optimal treatment of myelofibrosis (MF), with a focus on novel data and emerging strategies.

Please note that the slide thumbnails in this activity link to a PowerPoint slideset. This slideset may be downloaded by clicking on any of the thumbnails within the activity or by clicking here.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with MF do you provide care for in a typical month?

A 73-year-old woman has been newly diagnosed with primary MF. Ultrasound shows splenomegaly (12 cm below costal margin), and her symptoms include fatigue, significant night sweating, weight loss, and abdominal pain. Laboratory findings indicate the following: hemoglobin (Hgb) 11.7 g/dL, white blood cell (WBC) count 22 x 109/L with 1% blasts, and platelets 40 x 109/L. She is not considered a candidate for transplant.

In your current practice, which of the following would you choose as the optimal therapeutic strategy for this patient?

A 68-year-old woman was diagnosed with polycythemia vera in 2012; she received therapy with acetylsalicylic acid, hydroxyurea, and phlebotomy. Recently, she progressed to post–polycythemia vera MF after presenting with erythrocytosis, splenomegaly, and B symptoms. She began treatment with ruxolitinib 10 mg BID, but she experienced anemia requiring admissions and gastrointestinal toxicity. Her total symptom score (TSS) is 14, and ultrasound revealed a maximum spleen length of 22 cm (11 cm below costal margin). Her labs include the following: Hgb 7.1 g/dL; WBC count 35.5 x 109/L; platelets 70 x 109/L; 2% blasts.

In your current practice, which of the following would you choose as the optimal therapeutic strategy for this patient?

As reported at ASH 2023 for the phase III TRANSFORM-1 trial, each of the following is true regarding treatment with navitoclax plus ruxolitinib vs placebo plus ruxolitinib for patients with JAK inhibitor–naive, higher-risk MF, EXCEPT for which one of the following?